RxDoctor Payments Data

Srinivas Katragadda, MD

Pulmonary Disease · Toledo, OHNPI 1861483521

Payments from drug & device makers

$44,337in general payments, 2019–2025

Across 62 payments — averaging $715.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$43K
  • Baxter Healthcare$139
  • Intuitive Surgical$98
  • Boehringer Ingelheim$70
  • Inogen, Inc.$69
  • Astellas Pharma US Inc$60
  • plus $697 from 20 others

What the payments were for

  • Food & beverage$1,17497%
  • Education$403%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$44,337 in reported general payments places this provider in the 85th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$176,621
Medicare patients
654
Services billed
1,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter313$251,776
ZemairaAlpha-1-Proteinase Inhibitor13$117,828
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr151$82,331
Breo ElliptaFluticasone/Vilanterol173$81,195
Spiriva RespimatTiotropium Bromide84$56,073
Breztri AerosphereBudesonide/Glycopyr/Formoterol65$44,333
Dupixent PenDupilumab11$41,162
Stiolto RespimatTiotropium Br/Olodaterol Hcl54$35,116
EliquisApixaban40$29,174
Spiriva HandihalerTiotropium Bromide35$24,277
SymbicortBudesonide/Formoterol Fumarate94$24,226
DuleraMometasone/Formoterol53$19,963
XareltoRivaroxaban24$18,627
Albuterol Sulfate HfaAlbuterol Sulfate602$17,814
Incruse ElliptaUmeclidinium Bromide46$16,685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$43$448,103737 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$70$99,371155 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$43,204$73,856171 claims
PfizerEliquis$34$29,17440 claims
MerckDulera$58$19,96353 claims
Johnson & JohnsonXarelto$41$18,62724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →